Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,002
datasets available to search
ShareScore release 0.9.0
Dataset results
2,002 results for “sarcoma”
Histone H3K36M mutation impairs mesenchymal differentiation and drives sarcoma development
GEO Series GSE63195. Mus musculus. 10 samples. Type: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing.
Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
GEO Series GSE236289. Homo sapiens. 28 samples. Type: Expression profiling by high throughput sequencing; Other.
Next-generation RNA-sequencing data of models of Ewing sarcoma with modulated expression of the lncRNA HOTAIR
GEO Series GSE109483. Homo sapiens. 40 samples. Type: Expression profiling by high throughput sequencing.
Synergistic effects of TRAIL and taurolidine on soft tissue sarcoma cell lines
GEO Series GSE36572. Homo sapiens. 12 samples. Type: Expression profiling by array.
Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma [HS18_ChIP-seq]
GEO Series GSE266063. Homo sapiens. 7 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Transcriptome regulated by ENG and MMP14 in Ewing sarcoma cells
GEO Series GSE173154. Homo sapiens. 53 samples. Type: Expression profiling by array.
Expression data from Ewing's sarcoma tumor samples
GEO Series GSE37371. Homo sapiens. 39 samples. Type: Expression profiling by array.
Human sarcoma cell lines and untransformed cells
GEO Series GSE39262. Homo sapiens. 51 samples. Type: Expression profiling by array.
Ewing's sarcoma tumor samples
GEO Series GSE37372. Homo sapiens. 78 samples. Type: Non-coding RNA profiling by array; Expression profiling by array.
Ewing Sarcoma Institut Curie
Whole-genome sequencing of 112 Ewing sarcoma samples and matched germ line DNA.
Pediatric Ewing Sarcoma Dana-Farber Cancer Institute
Whole exome sequencing of 96 pediatric Ewing Sarcoma tumors and 11 cell lines.
Gabriella Miller Kids First (GMKF) Pediatric Research Program in Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial History of Cancer
Ewing sarcoma (EWS) is a deadly bone cancer that occurs in children and adolescents. Mounting evidence suggests that a genetic predisposition exists for this pediatric cancer, although the specific genetic contribution has yet to be identified. EWS has never been linked to a specific cancer predisposition syndrome, although several case reports have been published that describe siblings and cousins with EWS. Furthermore, neuroectodermal tumors appear to occur more commonly in families with EWS. The two consistent epidemiology findings in EWS include a very strong Caucasian predilection and increased rates of hernia in EWS patients and their family members. Finally, the role of genetic microsatellite repeats in EWS tumorigenesis has been recently described, and these GGAA microsatellites are polymorphic in repeat size and location across the genome.
Raw data for patients with giant axillary soft tissue sarcoma
<p>Raw data for 21 patients with giant axillary soft tissue sarcoma, who underwent limb salvage surgery with conventional preoperative planning based on each seperate images, or three dimensional multimodal reconstruction derived from these images, in West China Hospital Sichuan University. </p> <p>Eligibility requirements included biopsy-proven, resectable giant axillary STS (diameter > 5 cm), age > 14 years, and a clinical course aimed at curative limb salvage surgery. The exclusion criteria were severe systemic disease and intolerance to surgery.</p> <p>The patient enrolment period was from November 2019 to December 2020, whereas data collection was from November 2019 to June 2021. TThe median follow-up duration was 10 months (range, 6–18 months).</p> <p>Patient demographics data included sex, age, tumour size, histology type, the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading, stage, and neurovascular involvement. Outcome measures included surgical margins, surgical complications, operative time, blood loss, serum C-reactive protein and interleukin-6, length of hospital stay, and limb function.</p>
EWSR1-ATF1 dependent 3D connectivity regulates oncogenic and differentiation programs in Clear Cell Sarcoma
<p><strong>Chimeric proteins resulting from chromosomal translocations play a major role as driver oncogenes in cancer. Among them, fusions between EWSR1 and transcription factors (TFs) generate oncogenes with powerful chromatin regulatory activities, capable of establishing complex gene expression programs.</strong><strong> Specific fusion partners are implicated in distinct tumor types, suggesting that the oncogenic activity of EWSR1 fusions is determined by their DNA binding properties and the chromatin environment of precursor cells</strong><strong>. Here we combined functional epigenomics with nuclear topology mapping to define the epigenetic and 3D connectivity landscape of Clear Cell Sarcoma (CCS), one of the most aggressive forms of human cancer, which is driven by the </strong><em><strong>EWSR1-ATF1</strong></em><strong> fusion gene. We find that </strong><strong>EWSR1-ATF1 displays a distinctive DNA binding pattern that depends on the EWSR1 prion-like domain and is divergent from wild type ATF1. </strong><strong>EWSR1-ATF1 promotes ATF1 retargeting to new distal sites, leading to chromatin activation and the establishment of a 3D network that controls oncogenic and differentiation signatures shared with primary CCS tumors. Conversely, EWSR1-ATF1 depletion results in a marked </strong><strong>reconfiguration of 3D connectivity</strong><strong>, including the emergence of a new set of connections controlling neural crest-related developmental programs. Accordingly, interrogation of more than 160’000 single cell expression profiles from the human skin atlas reveals that loss of EWSR1-ATF1 expression induces a differentiated cell state that resembles cells in the Schwann cell-melanocytic axis. Taken together, our study uncovers the cooperativity network of EWSR1-ATF1, delineates the molecular underpinnings of its epigenetic function in CCS, and points to precursor cells in the neural crest lineage as candidate cells of origin for these tumors. </strong></p>
Dataset related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"</p><p>Abstract</p><p><strong>Purpose: </strong>The lung is the most frequent site of metastasis in patients with sarcoma. Pulmonary metastasectomy is the most common treatment performed. Stereotactic body radiation therapy (SBRT) has proven to be a potential alternative to resection. This prospective phase 2 study aimed to assess the role of SBRT for patients with lung metastases.</p><p><strong>Methods and materials: </strong>Adult patients with up to 4 lung metastases (LMs) ≤5 cm in diameter and unsuitable for surgery were included. Dose prescription was based on site and size: 30 Gy/1 fraction for peripheral lesions ≤10 mm, 60 Gy/3 fractions for peripheral lesions 11 to 20 mm, 48 Gy/4 fractions for peripheral lesions >20 mm, and 60 Gy/8 fractions for central lesions. The primary endpoint was the proportion of treated lesions free from progression at 12 months. Secondary endpoints were disease-free survival (DFS), overall survival (OS), and toxicity.</p><p><strong>Results: </strong>Between March 2015 and December 2020, 44 patients with a total of 71 LMs were enrolled. Twelve-month local control was 98.5% ± 1.4%, reaching the primary aim; the median DFS time was 12 months (95% CI, 8-16 months), and the 1-, 2-, 3-, 4-, and 5-year PFS rates were 50% ± 7.5%, 19.5% ± 6.6%, 11.7% ± 5.8%, 11.7% ± 5.8%, and 11.7% ± 5.8%, respectively. The median OS time was 49 months (95% CI, 24-49 months), and the 1-, 2-, 3-, 4-, and 5-year OS rates were 88.6% ± 4.7%, 66.7 ± 7.6%, 56.8% ± 8.4%, 53.0% ± 8.6%, and 48.2% ± 9.1%, respectively. Prognostic factors recorded as significantly affecting survival were age, grade of primary sarcoma, interval time from diagnosis to occurrence of LMs, and number of LMs. No severe pulmonary toxicity (grade 3-4) occurred.</p><p><strong>Conclusions: </strong>The study found a local control of LMs in almost all patients treated, with negligible toxicity. Survival was also highly satisfactory. Well-designed randomized trials comparing surgery with SBRT for patients with metastatic lung sarcoma are needed to confirm these preliminary data</p>
TARGET: Kidney, Clear Cell Sarcoma of the Kidney (CCSK)
Open the record for dataset details and reuse information.
Gabriella Miller Kids First (GMKF) Pediatric Research Program in Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial History of Cancer
Open the record for dataset details and reuse information.
Pediatric In Vivo Testing Program –Sarcoma, Kidney, and Liver Cancers
Open the record for dataset details and reuse information.
Pediatric In Vivo Testing Program – Sarcomas and other Solid Tumors
Open the record for dataset details and reuse information.
Sarcoma Alliance for Research through Collaboration
SARC has banked human biospecimens from sarcoma patients participating in our clinical trials into a single biorepository. The SARC Biospecimen Bank consists of thousands of specimens that are well-annotated and linked with patient clinical, treatment, and outcome data. This collection is designed to help qualified sarcoma investigators or organizations gain access to specimens to explore biomarkers, identify therapeutic targets, or make discoveries.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.